Second cancers at 4 ‐ 9‐year median · women with early poor prognosis breast cancer
High‐dose chemotherapy showed no clear difference in second cancers at 4 ‐ 9‐year median compared with chemotherapy without bone marrow transplant or stem cell rescue (high certainty).
1 finding from 1 review
Overall survival† · people with cutaneous melanoma
Polychemotherapy showed no clear difference in overall survival† compared with chemotherapy (high certainty).
1 finding from 1 review
HR 0.99 [0.85, 1.16]
594 participants
High
Progression‐freesurvival† · people with cutaneous melanoma
Polychemotherapy showed no clear difference in progression‐freesurvival† compared with chemotherapy (high certainty).
1 finding from 1 review
HR 1.07 [0.91, 1.25]
398 participants
High
Tumour response · people with cutaneous melanoma
Polychemotherapy probably leads to higher tumour response compared with chemotherapy (moderate certainty).
1 finding from 1 review
RR 1.27 [1.02, 1.58]
1885 participants
Moderate
Toxicity (≥ G3) · people with cutaneous melanoma
Polychemotherapy probably leads to higher toxicity (≥ G3) compared with chemotherapy (moderate certainty).
1 finding from 1 review
RR 1.97 [1.44, 2.71]
390 participants
Moderate
Overall survival (3 years) · people with resectable stage II and III rectal cancer undergoing preoperative chemoradiation followed by surgery
It is very uncertain whether combination chemotherapy changes overall survival (3 years) compared with single‐agent chemotherapy (very low certainty).
1 finding from 1 review
Disease-free survival · people with resectable stage II and III rectal cancer undergoing preoperative chemoradiation followed by surgery
It is very uncertain whether combination chemotherapy changes disease‐free survival (3 years) compared with single‐agent chemotherapy (very low certainty).
1 finding from 1 review
Complete response rate after preoperative chemoradiation (ypCR) · people with resectable stage II and III rectal cancer undergoing preoperative chemoradiation followed by surgery
Combination chemotherapy leads to higher complete response rate after preoperative chemoradiation (ypCR) compared with single‐agent chemotherapy (high certainty).
1 finding from 1 review
Toxicity ‐ early adverse events G3/4 · people with resectable stage II and III rectal cancer undergoing preoperative chemoradiation followed by surgery
Combination chemotherapy probably leads to higher toxicity ‐ early adverse events G3/4 compared with single‐agent chemotherapy (moderate certainty).
1 finding from 1 review
Metastases intra‐abdominal · people with resectable stage II and III rectal cancer undergoing preoperative chemoradiation followed by surgery
Combination chemotherapy showed no clear difference in metastases intra‐abdominal compared with single‐agent chemotherapy (moderate certainty).
1 finding from 1 review
Radiotherapy compliance · people with resectable stage II and III rectal cancer undergoing preoperative chemoradiation followed by surgery
Combination chemotherapy probably leads to lower radiotherapy compliance compared with single‐agent chemotherapy (moderate certainty).
1 finding from 1 review
Complete response · Kaposi sarcoma in children with HIV‐1 infection
It is very uncertain whether chemotherapy + ART changes complete Response to Tx compared with chemotherapy Alone (very low certainty).
1 finding from 1 review
RR 6.54 [1, 42.86]
36 participants
Very low
Complete response plus partial response Length of · Kaposi sarcoma in children with HIV‐1 infection
It is very uncertain whether chemotherapy + ART changes complete/Partial Response to Tx compared with chemotherapy Alone (very low certainty).
1 finding from 1 review
RR 1.47 [0.87, 2.49]
36 participants
Very low
Complete Among Known Outcome · Kaposi sarcoma in children with HIV‐1 infection
It is very uncertain whether chemotherapy + ART changes complete Among Known Outcome compared with chemotherapy Alone (very low certainty).
1 finding from 1 review
RR 4.25 [0.7, 25.91]
30 participants
Very low
Complete/Partial Among Known Outcome · Kaposi sarcoma in children with HIV‐1 infection
It is very uncertain whether chemotherapy + ART changes complete/Partial Among Known Outcome compared with chemotherapy Alone (very low certainty).
1 finding from 1 review
RR 1.01 [0.81, 1.27]
30 participants
Very low
All‐cause mortality · Kaposi sarcoma in children with HIV‐1 infection
It is very uncertain whether chemotherapy + ART changes mortality compared with chemotherapy Alone (very low certainty).
1 finding from 1 review
RR 0.46 [0.29, 0.73]
98 participants
Very low
Secondary malignant neoplasms · Patients with untreated Hodgkin lymphoma (advanced stages)
Dose‐intensified chemotherapy showed no clear difference in secondary malignant neoplasms compared with ABVD‐like chemotherapy (with or without radiotherapy (low certainty).
1 finding from 1 review
Death · Patients with untreated Hodgkin lymphoma (advanced stages)
Dose‐intensified chemotherapy showed no clear difference in death compared with ABVD‐like chemotherapy (with or without radiotherapy (moderate certainty).
1 finding from 1 review
Progression/relapse · Patients with untreated Hodgkin lymphoma (advanced stages)
Dose‐intensified chemotherapy probably leads to lower progression/relapse compared with ABVD‐like chemotherapy (with or without radiotherapy (moderate certainty).
1 finding from 1 review
Disease-free survival · neoadjuvant therapy for early triple‐negative breast cancer
Platinum‐containing chemotherapy leads to lower DFS at 2 years compared with chemotherapy without platinum (high certainty).
2 findings from 1 review